stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Return on equity
Grifols, S.A.'s return on equity over the twelve months to 30 September 2026 was 5.80%, up 0.7 percentage points from fiscal 2025 (5.08%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 18.2% (fiscal 2017); the current reading is higher than 67% of that period. That is in line with the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 5.08% | 3.19 |
| FY2024 | 1.89% | 1.16 |
| FY2023 | 0.73% | (1.77) |
| FY2022 | 2.50% | 2.50 |
| FY2022 | 0.00% | (2.73) |
| FY2021 | 2.73% | 2.73 |
| FY2021 | 0.00% | (9.21) |
| FY2020 | 9.21% | 9.21 |
| FY2020 | 0.00% | (10.60) |
| FY2019 | 10.6% | 10.60 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| NVO Novo Nordisk A/S compare | 58.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| GSK GSK PLC Sponsored ADR compare | 25.5% |
| OGN Organon & Co. compare | 20.3% |
| GRFS Grifols, S.A. | 5.80% |
| BIIB Biogen Inc. compare | 1.87% |
| SNY Sanofi compare | 0.00% |
| NSRX Nasus Pharma Ltd. compare | 0.00% |
| AMRN Amarin Corporation PLC compare | −4.24% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement